Early and intensive treatment of age-related macular degeneration with bevacizumab is associated with greater long-term improvements in visual acuity than are ranibizumab or aflibercept, a real ...

Bevacizumab was administered at a dose of 10 mg per kilogram of body weight intravenously every 2 weeks, and erlotinib was administered at a dose of 150 mg orally once daily during each 28-day cycle.

The most common TRAEs of any grade were acneiform rash (93%), diarrhea (89%), proteinuria (78%), and dry skin (64%).

PURPOSEThe use of bevacizumab in glioblastoma has been associated with increased progression-free survival and improvement in symptoms and quality of life. There are no clinical indicators on how to ...

First-line treatment with alectinib and bevacizumab appears to be effective for patients with ALK-rearranged, metastatic NSCLC, according to researchers.

EGFR amplification was more frequent in patients who received bevacizumab for ≤6 months (46% v 20%). Multivariate analysis showed that CDK4 amplification was associated with longer time on bevacizumab ...

Targeted Oncology connects oncology professionals with updates on immunotherapy, biomarkers, cancer pathways, and targeted ...

LYTENAVA™ is the first and only approved ophthalmic formulation of bevacizumab for the treatment of wet AMD in the European Union (EU) and United Kingdom (UK)2.8 million injections of repackaged ...

CHICAGO — Anlotinib plus chemotherapy demonstrated similar efficacy as bevacizumab plus chemotherapy for certain patients with unresectable metastatic colorectal cancer, according to findings ...

BioDlink's Bevacizumab Injection has been granted marketing authorization by Nigeria's National Agency for Food and Drug Administration and Control (NAFDAC), following GMP certifications in Brazil ...